ER+/HER2+ breast cancer: are we really de-escalating?
Auteurs : de Azambuja E, Piccart-Gebhart M
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 875-877
Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
Auteurs : Eiger D, Pondé NF, de Azambuja E
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 1823-1843
Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
Auteurs : Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, Tkint de Roodenbeke D, de Azambuja E, Ignatiadis M, Demeestere I
Année : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 237-243
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
Auteurs : Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen MB, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA Jr
Année : 2018
Journal : J Natl Cancer Inst
Volume : 110(4)
Pages : 426-429
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Auteurs : Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000361
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Auteurs : Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 1497-1508
Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.
Auteurs : Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O
Année : 2018
Journal : Front Oncol
Volume : 8
Pages : 156
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Auteurs : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Année : 2018
Journal : JAMA Oncol
Volume : 4
Pages : e181564
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Auteurs : Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, de Azambuja E
Année : 2018
Journal : Expert Rev Anticancer Ther
Volume : 18
Pages : 629-649
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
Auteurs : Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, Preusser M, Saba L
Année : 2018
Journal : Crit Rev Oncol Hematol
Volume : 126
Pages : 135-144
Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
Auteurs : Lambertini M, Viglietti G, de Azambuja E
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000350
Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: a TransHERA study.
Auteurs : Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Pritchard KI, Gelber Rd, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart M, Dowsett M
Année : 2018
Journal : Clin Cancer Res
Volume : 24(13)
Pages : 3079-3086
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.
Auteurs : Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber Rd, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA
Année : 2018
Journal : Int J Radiat Oncol Biol Phys
Volume : 101(2)
Pages : 316-324.
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.
Auteurs : Maurer C, Ferreira AR, Martel S, Lambertini M, Pondé N, Aftimos P, de Azambuja E, Piccart-Gebhart M
Année : 2018
Journal : Breast
Volume : 39
Pages : 14-18
Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
Auteurs : Poggio F, Lambertini M, de Azambuja E
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000324
Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients.
Auteurs : Pondé N, de Azambuja E
Année : 2018
Journal : Chin Clin Oncol
Volume : 7(1)
Pages : 4
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Auteurs : Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart-Gebhart M, Suter T, de Azambuja E
Année : 2018
Journal : Breast Cancer Res Treat
Volume : 168(3)
Pages : 631-638
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
Auteurs : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Année : 2018
Journal : Eur J Cancer
Volume : 89
Pages : 42-48
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
Auteurs : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Année : 2018
Journal : Int J Oncol
Volume : 52(2)
Pages : 424-432
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Auteurs : Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M
Année : 2018
Journal : Cancer Treat Rev
Volume : 62
Pages : 123-132